Navigation Links
Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
Date:5/8/2009

igational drug which has recently completed a Phase 3 trial for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including risks relating to our terminated clinical trials, our remaining contractual commitments, the success of our efforts to maximize the value of our cash and other assets for our shareholders, and levels of future operations and expenditures, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.

                               CONDENSED STATEMENTS OF OPERATIONS
                      (Unaudited - in thousands, except per share amounts)


                               Three months ended       Nine months ended
                                    March 31,                March 31,
                                2009        2008         2009        2008

     REVENUES
         Royalty                1,505       2,161        5,590        6,245
         Technology sale
          and collaboration
          services              1,508       1,523        4,479        5,002

     Total revenues             3,013       3,684       10,069       11,247

     EXPENSES
         Research and
          development           1,857       5,945       17,701       18,822
         General and
          administrative        1,438       1,757        3,970        5,327

           Total expenses       3,295       7,702       21,671       24,149

     Operating los
'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
2. Neurobiological Technologies Reports Second Quarter Financial Results
3. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
4. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
7. Neurobiological Technologies Reports Going Concern Qualification
8. Steven H. Kane Appointed as President and Chief Executive Officer of Patient Safety Technologies, Inc.
9. Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009
10. EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results
11. Greenway Medical Technologies PrimeSuite Solution Provides OB/GYN Physicians With Instant Access to Labor and Delivery Information at Point-of-Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... (PRWEB) March 31, 2015 Williams ... a repair visit when their home comfort is ... and make the visit fit into the customer’s ... provide fast, quality repair at requested times. ... and commercial customers in the Indianapolis area can ...
(Date:3/31/2015)... 2015 Tickets are now on sale ... tradition since 1973. The 2015 Spring production, Fairy Tales ... Ice. On April 24 in partnership with the Alzheimer's ... night tribute to the Pat Bowlen family, long-time partners ... the opening event proceeds will go to the Alzheimer's ...
(Date:3/31/2015)... Fitbody Personal Training LLC invites participants to get ready for ... workouts away from the gym and prepare to energize the ... LLC. The classes are moving outdoors. , Personal trainer ... outdoors on Thursday evenings starting April 2, 2015 and ending ... starts on April 11th and ends on May 16, 2015. ...
(Date:3/31/2015)... QMedET Solutions, LLC, is now ... industry’s most advanced speech recognition technology to another ... now experience the full benefits of a speech-enabled ... support services that ensure successful integration with leading ... proud to provide Dragon Medical Practice Edition 2 ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 The Oliver ... page in response to client requests after Zofran ... that Zofran manufacturer, GlaxoSmithKline (GSK) failed to warn physicians ... associated with the medication and “illegally and fraudently” promoted ... women without receiving approval for that use from the ...
Breaking Medicine News(10 mins):Health News:Williams Comfort Air Launches Online Scheduling Tool to Indianapolis-Area Home and Business Owners 2Health News:FitBody Personal Training LLC Announces its Personal Training Classes are Moving Outdoors 2Health News:QMedET Solutions Announces Addition of Dragon® Medical Practice Edition 2 to its Roster of Products 2Health News:Zofran Lawsuit Information Page Launched In Response To Clients Request For Information On Potential For Zofran Birth Defects, The Olive Law Group 2Health News:Zofran Lawsuit Information Page Launched In Response To Clients Request For Information On Potential For Zofran Birth Defects, The Olive Law Group 3
... According to researchers at Hopkins University, they have found a ... in the immune system, surpassing an obstacle to certain ... from improving the body's immune response to developing cancer vaccines ... cells form the core of the blood system.// They can ...
... micro capsule coated with silicon, which could save the ... absorbing nutrients from the body //and stimulates the ... than onece a day to maintain their blood sugar ... Desai of the University of Illinois at Chicago Ms ...
... leading cause of disability in the United States, affects ... advances in treatment options and educational efforts,// depression has ... US. In fact, a recent study stressed that as ... fail to receive adequate treatment. ,Americans have ...
... the greatest increase in bone mineral after the growth spurt ... are in danger of suffering broken bones in later life,// ... skeleton during a vital two-year window before puberty, which is ... be between 10 and 12 and in boys it is ...
... electromagnetic fields (EMF) at home could double the risk ... //The three-year review was carried out for the International ... epidemiologists from major institutions around the world. ,Leukemia, ... third of all childhood cancers - around the world ...
... common learning disorder, affects nearly one in 24 people. ... read, write and spell. Dyslexia was found to have ... of the brain that controls movement, co-ordination and balance, ... led by Professor Roderick Nicolson, compared the brain activity ...
Cached Medicine News:Health News:A new study surpasses Gene Therapy Hurdle 2
(Date:3/31/2015)... , March 31, 2015 The Medical ... featured in the American Medical Group Association,s "High ... AMGA,s "High Performing Health" production is ... facing the nation,s healthcare system in delivering better ... profiled along with other leading organizations in the ...
(Date:3/31/2015)... March 31, 2015 According ... and Chemical Instrumentation Market (Chromatography, Electrophoresis, DNA Sequencer, PCR, ... Incubator, Fume Hood, Centrifuge) - Global Forecast to ... and Chemical Instrumentation Market is expected to reach ... from 2014 to 2019. Browse ...
(Date:3/31/2015)... March 31, 2015 Ryan & Maniskas, ... of directors of Hyperion Therapeutics, Inc. ("Hyperion" or the ... fiduciary duty and other violations of law related to ... Pharma plc in a transaction valued at approximately $1.1 ... and would like to learn more about this class ...
Breaking Medicine Technology:AMGA's High Performing Health News Program Features The Medical Letter 2Life Science and Chemical Instrumentation Market Worth $48.84 Billion by 2019 2Life Science and Chemical Instrumentation Market Worth $48.84 Billion by 2019 3Life Science and Chemical Instrumentation Market Worth $48.84 Billion by 2019 4Life Science and Chemical Instrumentation Market Worth $48.84 Billion by 2019 5Ryan & Maniskas, LLP Announces Investigation of Hyperion Therapeutics, Inc. 2
... patients with acute coronary syndrome being managed with ... ... TOKYO and INDIANAPOLIS, Feb. 21 Daiichi,Sankyo Company, Limited (TSE: 4568) ... the U.S. Food and Drug Administration (FDA) accepted,and designated Priority Review ...
... 21 MonoSol Rx, a drug delivery,company specializing ... it has successfully completed a pilot clinical study ... 5-HT3 receptor antagonist,used in the prevention and treatment ... film formulation of ondansetron was studied against,GlaxoSmithKline,s Zofran ...
Cached Medicine Technology:FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel 2FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel 3MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study 2MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: